Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of XNW4107 in Healthy Young and Elderly Subjects
NCT04801043Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pibozobactam in bacterial infection (4 arms), sponsored by Evopoint Biosciences. Primary endpoints: Total body clearance, Area under the curve from time zero to last quantifiable sample and 8 more. Started Mar 2021; status: completed.
02
Drugs
pibozobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04801043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801043.